2022
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
Press BH, Jones T, Olawoyin O, Lokeshwar SD, Rahman SN, Khajir G, Lin DW, Cooperberg MR, Loeb S, Darst BF, Zheng Y, Chen RC, Witte JS, Seibert TM, Catalona WJ, Leapman MS, Sprenkle PC. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science 2022, 37: 113-119. PMID: 35243396, PMCID: PMC8883188, DOI: 10.1016/j.euros.2022.01.008.Peer-Reviewed Original ResearchDecipher scoreMultivariable logistic regressionGleason grade groupActive surveillanceProstate cancerBiopsy GleasonBiopsy upgradingGG2 diseaseGenomic classifierFavorable intermediate-risk prostate cancerBiopsy Gleason grade groupIntermediate-risk prostate cancerLogistic regressionDecipher genomic classifierHigher Decipher scoresRetrospective cohort studyBaseline clinical variablesHigh-grade diseaseBiopsy reclassificationDecipher testDecipher testingGleason upgradeCohort studyMedian ageClinical variables
2021
Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI
Press BH, Khajir G, Ghabili K, Leung C, Fan RE, Wang NN, Leapman MS, Sonn GA, Sprenkle PC. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology 2021, 155: 96-100. PMID: 34087311, DOI: 10.1016/j.urology.2021.05.035.Peer-Reviewed Original ResearchConceptsPSA densityActive surveillanceConfirmatory biopsyPathologic upgradeNegative MRIProstate volumeProstate cancerFavorable intermediate-risk prostate cancerNegative baselineIntermediate-risk prostate cancerLow-grade prostate cancerLower prostate volumeMedian PSA densityNormal baseline MRIUpgraded Gleason scoreCohort of patientsSubset of patientsLarge academic centerPI-RADS 2Intensity of surveillanceAbility of PSABiopsy upgradeGG1 cancerGleason upgradeMedian PSA